Clinical Case: 58-Year-Old Breathless Smoker — Acute COPD Exacerbation

Version 1.0 — Published April 2026

The case

A 58-year-old male retired factory worker presents to the emergency department with worsening breathlessness for 5 days. He reports that he can no longer walk from his bed to the bathroom (a distance of 10 meters) without stopping to catch his breath. He describes increased sputum production — now thick, yellow-green, and approximately 2 tablespoons per episode (up from his usual clear mucoid sputum). He also reports low-grade fever (100.4 F) for 3 days and audible wheezing noticed by his wife.

He has smoked 20 bidi per day for 30 years (30 pack-year equivalent). He was diagnosed with "asthma" 8 years ago at a local clinic and uses a salbutamol inhaler intermittently. He has had 3 similar episodes in the past 18 months, the last requiring a 5-day hospital stay 4 months ago. He takes no regular medications and has not received any vaccinations.

History and examination

Smoking history is the central anchor in this vignette. A 30-pack-year history in a male over 40 with progressive dyspnea and recurrent exacerbations points overwhelmingly to COPD rather than asthma. In India, COPD affects an estimated 55.3 million adults (Global Burden of Disease Study, 2019), with bidi smoking and biomass fuel exposure as the two dominant risk factors.

The misdiagnosis as "asthma" is deliberate in this stem — NEET PG frequently tests the asthma-COPD distinction in middle-aged smokers.

General examination:

• Pulse: 110 bpm, regular
• Blood pressure: 140/85 mmHg
• Respiratory rate: 28/min
• SpO2: 88% on room air
• Temperature: 100.4 F (38.0 C)
• Barrel chest — increased anteroposterior diameter (AP:lateral ratio approaching 1:1, normal is 5:7)
• Use of accessory muscles of respiration (sternocleidomastoid, scalene)
• Pursed-lip breathing — the patient exhales through pursed lips, which creates auto-PEEP and prevents small airway collapse
• Nicotine staining on fingers

Respiratory examination:

• Inspection: barrel chest, reduced chest expansion bilaterally, intercostal recession
• Palpation: reduced vocal fremitus bilaterally (hyperinflated lungs transmit vibrations poorly)
• Percussion: hyperresonant bilaterally (air trapping). Liver dullness pushed down (flattened diaphragm). Obliteration of cardiac dullness in the left parasternal region
• Auscultation: decreased breath sounds bilaterally with prolonged expiratory phase. Scattered polyphonic expiratory wheezes. No crackles (differentiates from pneumonia or pulmonary edema at this stage)

Cardiovascular: Loud P2 (suggesting pulmonary hypertension). No pedal edema currently (no cor pulmonale yet).

Differential diagnosis

Acute COPD exacerbation is the clinical anchor, but the differential for acute dyspnea in a chronic smoker includes several conditions that can mimic or coexist with COPD:

The combination of chronic smoking history + barrel chest + hyperresonance + purulent sputum increase + hypoxia is classic acute exacerbation of COPD. The Anthonisen criteria confirm the diagnosis severity.

Investigations

Arterial blood gas (ABG) is the most critical investigation in acute COPD exacerbation — it determines management strategy.

This patient's ABG on room air:

• pH: 7.31 (acidic — normal 7.35-7.45)
• PaCO2: 58 mmHg (elevated — normal 35-45 mmHg)
• PaO2: 52 mmHg (hypoxemic — normal 80-100 mmHg)
• HCO3: 30 mEq/L (elevated — normal 22-26 mEq/L)
• SpO2: 86% (on ABG sample)

ABG interpretation (step by step):

1. pH 7.31 = acidosis
2. PaCO2 58 = respiratory acidosis (CO2 is the acid driver)
3. HCO3 30 = metabolic compensation (kidneys retaining bicarbonate)
4. Expected HCO3 for chronic respiratory acidosis: 24 + 3.5 x [(58-40)/10] = 24 + 6.3 = 30.3 mEq/L — matches the actual HCO3
5. But pH is still acidic (below 7.35) despite full chronic compensation — this means there is an acute-on-chronic respiratory acidosis (the acute exacerbation has raised CO2 beyond the kidney's compensated baseline)

This ABG pattern — acidic pH with elevated PaCO2 and appropriately elevated HCO3 — is the classic NEET PG ABG for COPD exacerbation.

Other investigations:

• Chest X-ray: hyperinflated lungs (flat diaphragm, more than 6 anterior ribs visible above the diaphragm), increased retrosternal air space on lateral view, attenuated vascular markings (oligemia in emphysema), no focal consolidation
• CBC: leukocytosis (WBC 13,500/mm3 with neutrophil predominance — supports bacterial infection trigger)
• Sputum culture: sent before starting antibiotics (common isolates: H. influenzae, S. pneumoniae, M. catarrhalis)
• ECG: P-pulmonale (peaked P waves in lead II, >2.5 mm — right atrial enlargement), right axis deviation, low voltage complexes (hyperinflated lungs increase distance from heart to chest leads)
• Spirometry (NOT during acute exacerbation — done after stabilization): expected to show FEV1/FVC <0.7 post-bronchodilator, FEV1 likely 30-49% predicted (GOLD 3, severe)

Diagnosis

Acute exacerbation of COPD (Anthonisen Type I, severe) with acute-on-chronic respiratory acidosis. Likely GOLD stage 3 (severe airflow limitation) based on clinical severity and history of recurrent exacerbations.

Anthonisen classification for this patient:

All three cardinal symptoms are present = Type I (severe) exacerbation. This classification directly determines antibiotic indication — antibiotics are recommended for Type I and Type II exacerbations.

GOLD severity staging (for stable COPD, assessed after recovery):

Management

Management of acute COPD exacerbation follows a stepwise approach. The order matters — NEET PG tests the sequence, not just the drugs.

Immediate management (first 60 minutes)

1. Controlled oxygen therapy — target SpO2 88-92% using a Venturi mask (FiO2 24-28%). The Venturi mask delivers precise FiO2 regardless of respiratory rate, unlike nasal prongs. Start at 24% (blue adapter) and titrate up. Never use high-flow oxygen (above 35% FiO2) without ABG monitoring — COPD patients with chronic hypercapnia may develop CO2 narcosis.
2. Nebulized short-acting bronchodilators — salbutamol 2.5-5 mg + ipratropium bromide 0.5 mg nebulized every 20 minutes for 3 doses, then every 4-6 hours. The combination is more effective than either agent alone (Cochrane review, 2019).
3. Systemic corticosteroids — prednisolone 40 mg orally or IV methylprednisolone 40 mg. The REDUCE trial (JAMA, 2013) demonstrated that 5 days is non-inferior to 14 days. Continue for 5-7 days total. Do not taper — short courses do not require tapering.
4. Antibiotics — indicated in this patient (Anthonisen Type I). Start amoxicillin-clavulanate 625 mg TDS or doxycycline 100 mg BD. If Pseudomonas risk (FEV1 <30%, frequent exacerbations, recent antibiotics): levofloxacin 750 mg OD or piperacillin-tazobactam.

Reassess at 1-2 hours (the NIV decision point)

Repeat ABG after 1-2 hours of medical therapy. This is the key decision point that NEET PG tests:

For this patient: pH 7.31 with PaCO2 58 mmHg after initial medical therapy qualifies for NIV. BiPAP reduces work of breathing, improves gas exchange, reduces intubation rates by 50%, and reduces in-hospital mortality by 20% (Plant et al., Lancet, 2000).

NIV contraindications (commonly tested):

• Respiratory arrest or severe hemodynamic instability
• Inability to protect airway (reduced consciousness, excessive secretions)
• Facial trauma or surgery precluding mask fit
• pH below 7.20 (relative — some centers trial NIV even here, but intubation threshold is lower)

Practice medicine MCQs on pulmonology and respiratory physiology to strengthen your COPD clinical reasoning. For a comprehensive review of medicine high-yield topics, see our NEET PG medicine guide.

Discharge planning and prevention

After stabilization (usually 5-7 days for hospitalized patients):

1. Optimize maintenance inhalers — LAMA (tiotropium) + LABA (formoterol) combination. Add ICS (budesonide) only if eosinophils above 300 cells/uL or frequent exacerbations despite dual bronchodilator therapy. The GOLD 2024 report specifically discourages ICS monotherapy or routine ICS use in COPD.
2. Smoking cessation — the single most effective intervention to slow FEV1 decline. NRT (nicotine patches) + behavioral counseling. Varenicline doubles quit rates compared to placebo.
3. Vaccinations — annual influenza vaccine + pneumococcal vaccine (PCV20 or PPSV23) + COVID-19 vaccine. Influenza vaccination reduces COPD exacerbation-related hospitalizations by 40%.
4. Pulmonary rehabilitation — structured exercise training for 6-12 weeks, starting within 4 weeks of discharge. Reduces hospital readmissions by 25% (Cochrane review, 2021).

How NEET PG tests COPD exacerbation

COPD exacerbation is tested through four dominant patterns in NEET PG, contributing 2-3 questions per paper:

Pattern 1 — The ABG question: Given ABG values (pH, PaCO2, HCO3, PaO2), identify the acid-base disturbance. The trap: confusing acute respiratory acidosis (normal HCO3, very acidic pH) with acute-on-chronic (elevated HCO3 from chronic compensation, mildly acidic pH). Always calculate the expected HCO3 for the given PaCO2.

Pattern 2 — The oxygen therapy question: Target SpO2 in COPD is 88-92%. The most common wrong answer chosen is 94-98% (which applies to non-COPD patients). The stem may disguise this as "a patient with known COPD and CO2 retention" and ask which oxygen delivery device to use — the answer is Venturi mask for precise FiO2 control.

Pattern 3 — The NIV indication: A patient with COPD exacerbation and pH 7.28-7.34 despite initial bronchodilators. The answer is BiPAP. The trap: choosing invasive ventilation (intubation) too early — NIV is first-line when pH is between 7.25-7.35.

Pattern 4 — The Anthonisen classification: Three cardinal symptoms (increased dyspnea, sputum volume, sputum purulence). Antibiotics are indicated in Type I (all three) and Type II (two of three). Type III (one symptom) does not require antibiotics.

High-yield one-liners for last-day revision:

• Pink puffer = emphysema (thin, dyspneic, relatively preserved PaO2)
• Blue bloater = chronic bronchitis (overweight, cyanotic, hypercapnic, peripheral edema)
• Barrel chest + hyperresonance + decreased breath sounds = emphysema/COPD (distinguish from bilateral pneumothorax)
• Venturi mask is the device of choice for controlled oxygen in COPD
• Alpha-1 antitrypsin deficiency causes early-onset emphysema (below age 45) with lower lobe predominance — a classic NEET PG association

Frequently asked questions

What is the most common cause of COPD exacerbation?

Respiratory tract infections cause 50-70% of COPD exacerbations. Bacterial infections (Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis) account for roughly half of infectious exacerbations, with viral infections (rhinovirus, influenza, RSV) causing most of the rest. Air pollution, non-adherence to inhalers, and pulmonary embolism are other important triggers tested in NEET PG.

What is the target SpO2 in acute COPD exacerbation?

The target SpO2 in COPD exacerbation is 88-92%, not the 94-98% used for most other conditions. COPD patients with chronic CO2 retention rely partly on hypoxic drive for respiration. Excessive oxygen (SpO2 above 92%) suppresses this drive, worsens hypercapnia, and can cause CO2 narcosis. This is one of the most frequently tested oxygen therapy concepts in NEET PG.

What are the Anthonisen criteria for COPD exacerbation?

The Anthonisen criteria classify COPD exacerbation severity using three cardinal symptoms: increased dyspnea, increased sputum volume, and increased sputum purulence. Type I (severe) has all three symptoms. Type II (moderate) has two of three. Type III (mild) has one symptom plus at least one minor criterion (upper respiratory infection in past 5 days, fever, increased wheezing, increased cough, or heart rate/respiratory rate increase of 20% above baseline).

When is NIV indicated in COPD exacerbation?

Non-invasive ventilation (BiPAP) is indicated when respiratory acidosis persists (pH 7.25-7.35, PaCO2 above 45 mmHg) despite optimal medical therapy including controlled oxygen and nebulized bronchodilators. NIV reduces intubation rates by 50% and mortality by 20% in moderate acidosis. Contraindications include pH below 7.25 (relative), facial trauma, inability to protect airway, and hemodynamic instability.

Which antibiotics are recommended for COPD exacerbation?

Antibiotics are indicated when at least two of three Anthonisen criteria are present, especially with increased sputum purulence. First-line options are amoxicillin-clavulanate, doxycycline, or a macrolide (azithromycin). For severe exacerbations or patients with risk factors for Pseudomonas (frequent exacerbations, FEV1 below 30%, recent hospitalization), respiratory fluoroquinolones (levofloxacin, moxifloxacin) or piperacillin-tazobactam are preferred.

How does ABG differ in compensated vs decompensated COPD?

Compensated COPD shows chronic respiratory acidosis with metabolic compensation: elevated PaCO2 (50-60 mmHg), near-normal pH (7.35-7.38), and elevated bicarbonate (28-34 mEq/L). Decompensated COPD (acute-on-chronic) shows acute worsening: higher PaCO2 (60-80+ mmHg), acidic pH (below 7.35), and bicarbonate that has not risen enough to compensate. The pH is the key differentiator — if pH is below 7.35 with elevated PaCO2, the acidosis is uncompensated.

What is the GOLD classification of COPD?

GOLD classifies airflow limitation severity by post-bronchodilator FEV1/FVC ratio below 0.7 plus FEV1 percentage of predicted: GOLD 1 (mild) FEV1 at or above 80%, GOLD 2 (moderate) 50-79%, GOLD 3 (severe) 30-49%, GOLD 4 (very severe) below 30%. The 2024 GOLD report also uses the ABE assessment tool combining symptoms (mMRC/CAT scores) and exacerbation history to guide treatment escalation.

What is the role of systemic corticosteroids in COPD exacerbation?

Systemic corticosteroids shorten recovery time, improve FEV1, and reduce treatment failure rates by 30-40%. The REDUCE trial (JAMA, 2013) showed 5 days of prednisolone 40 mg daily is as effective as 14 days. GOLD 2024 recommends 5-7 days of oral prednisolone 40 mg or IV methylprednisolone for hospitalized patients. Prolonged courses increase hyperglycemia and infection risk without additional benefit.

Sources and references

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 Report — COPD classification, assessment, and pharmacotherapy algorithm.
2. Harrison's Principles of Internal Medicine, 21st Edition (Loscalzo et al., 2022) — Chapter on COPD, pathophysiology and acute exacerbation management.
3. Plant PK et al., "Early use of non-invasive ventilation for acute exacerbations of COPD on general respiratory wards," Lancet, 2000 — landmark NIV trial reducing intubation and mortality.

Strengthen your medicine subject coverage and build clinical reasoning by working through pulmonology vignettes on the NEETPGAI practice platform. Ready for unlimited AI-powered MCQs with detailed explanations? Explore NEETPGAI Pro.

For personalized study guidance on respiratory medicine and other high-yield topics, try the AI Tutor — it adapts to your weak areas and explains concepts the way a senior resident would.

---

Written by: NEETPGAI Editorial Team Reviewed by: Pending SME Review Last reviewed: April 2026

This article is reviewed by qualified medical professionals for clinical accuracy and exam relevance. For corrections or updates, contact the editorial team.